Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SinoMab BioScience Limited (3681.HK)
Tai Po, HK
SinoMab BioScience Limited is a biopharmaceutical enterprise that specializes in the comprehensive process of discovering, developing, producing, and marketing therapeutic solutions for various immunological disorders. Their approach predominantly involves monoclonal antibody (mAb)-based biologics. A key asset in their portfolio is SM03, an innovative anti-CD22 monoclonal antibody. This drug is currently in Phase III clinical trials for rheumatoid arthritis (RA), with additional clinical investigations underway for other immune-related conditions such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company is also progressing with SN1011, a Bruton's tyrosine kinase inhibitor. This compound is in Phase II clinical trials for pemphigus and has commenced Phase I trials for multiple sclerosis, SLE, and neuromyelitis optica spectrum disorder (NMOSD). Furthermore, SinoMab maintains an active preclinical pipeline. This includes SM17, which targets asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06, intended for RA, SLE, NMOSD, and SS; SM09, in development for NHL and RA; and TNF2, focused on a range of autoimmune diseases. Founded in 2001, SinoMab BioScience Limited is based in Pak Shek Kok, Hong Kong, and conducts its business activities across Mainland China, the Cayman Islands, and Hong Kong.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.33% | -4.62% | -17.33% | -38.61% | -18.95% | -7.46% | -16.22% | -31.87% | -65.07% | -79.33% | -79.33% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%-100.0% Q4'25: +100.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+50.9% ★ Q4'25: +64.0% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-26.9% Q4'25: -60.6% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+14.3% Q4'25: +34.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-2.72× Q4'25: -1.20× (vs Q4'23)
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
4.03M
est: 340.54M (-98.8%)
|
1.37M
est: 3.94M (-65.4%)
|
2.03M
est: 364.24M (-99.4%)
|
—
est: 3.91M (-100.0%)
|
7.82M
7.82M – 7.82M
+100.0% YoY
|
15.64M
15.64M – 15.64M
+100.0% YoY
|
| EBITDA |
-244.29M
est: -340.54M (+28.3%)
|
-200.46M
est: -3.94M (-4,983.7%)
|
-142.79M
est: -218.54M (+34.7%)
|
-124.70M
est: -2.35M (-5,213.7%)
|
-4.69M
-4.69M – -4.69M
-100.0% YoY
|
-9.39M
-9.39M – -9.39M
-100.0% YoY
|
| EBIT |
-258.93M
est: -340.54M (+24.0%)
|
-236.53M
est: -3.94M (-5,898.3%)
|
-161.93M
est: -218.54M (+25.9%)
|
-124.70M
est: -2.35M (-5,213.7%)
|
-4.69M
-4.69M – -4.69M
-100.0% YoY
|
-9.39M
-9.39M – -9.39M
-100.0% YoY
|
| Net Income |
-284.16M
est: -55.41M (-412.8%)
|
-243.11M
est: -201.18M (-20.8%)
|
-185.14M
est: -67.74M (-173.3%)
|
-102.27M
est: -228.08M (+55.2%)
|
-228.08M
-228.08M – -228.08M
+0.0% YoY
|
-240.09M
-240.09M – -240.09M
-5.3% YoY
|
| SGA |
82.59M
est: 9.27B (-99.1%)
|
97.62M
est: 107.31M (-9.0%)
|
67.72M
est: 9.57B (-99.3%)
|
45.18M
est: 102.80M (-56.0%)
|
205.61M
205.61M – 205.61M
+100.0% YoY
|
411.22M
411.22M – 411.22M
+100.0% YoY
|
| EPS |
-0.29
est: -0.05 (-461.9%)
|
-0.24
est: -0.19 (-28.1%)
|
-0.17
est: -0.06 (-208.0%)
|
-0.08
est: -0.19 (+55.1%)
|
-0.19
-0.19 – -0.19
+0.0% YoY
|
-0.20
-0.20 – -0.20
-5.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Shui On Leung | Founder, Chairman & Chief Executive Officer | 8M | — |
| Jianping Hua | Chief Financial Officer | — | male |
| Lixin Zhang Auberson | Chief Medical Officer | — | — |
| Fang Liang | Chief Operating Officer | — | female |
| Wai Ki Lai | Company Secretary | — | female |
| Wai Lai | Company Secretary | — | female |
| Yuande Zhang | Director of Marketing | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3681.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
